Observational Registry Study of Quality of Life When Treating BTcP With Abstral (RELIEF)
Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstral® (Fentanyl) Sublingual Tablets
Sponsor: Galena Biopharma, Inc.
A observational or N/A phase clinical study on Breakthrough Cancer Pain and Quality of Life, this trial is completed. The trial is conducted by Galena Biopharma, Inc. and has accumulated 8 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Galena Biopharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .